Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Key Points

• Kiniksa beat quarterly expectations: EPS came in at $0.56 versus the $0.37 consensus, while revenue reached $285.97 million compared with estimates of $260.66 million.
• Shares remain elevated: KNSA has a $5.69 billion market capitalization and traded within a 52-week range of $35.20 to $84.06, with a reported PE ratio of 75.24.
• Analysts remain broadly bullish: Eight analysts rate the stock a Buy and one rates it Hold, producing a “Moderate Buy” consensus and an average price target of $93.14; meanwhile, two insiders recently sold shares.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19, FiscalAI reports. The business had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%.

Kiniksa Pharmaceuticals International Price Performance

KNSA opened at $72.98 on Tuesday. The business has a 50-day moving average of $78.03 and a 200-day moving average of $59.00. Kiniksa Pharmaceuticals International has a fifty-two week low of $35.20 and a fifty-two week high of $84.06. The company has a market capitalization of $5.69 billion, a PE ratio of 75.24 and a beta of 0.04.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 4,600 shares of the business's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the company's stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director directly owned 11,672 shares of the company's stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The SEC filing for this sale provides additional information. 51.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of research analyst reports. Wells Fargo & Company began coverage on Kiniksa Pharmaceuticals International in a research note on Wednesday, September 30th. They issued an "overweight" rating and a $87.00 price target on the stock. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Canaccord Genuity Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.14.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.